EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017.
“This is a very exciting time for Adamas, as we are potentially at the cusp of transitioning from a company focused on product development to a commercial entity marketing its own medicines,” stated Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. “We look forward to hearing from the FDA regarding the potential approval of ADS-5102 for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease. If approved, ADS-5102 will be the first and only approved medicine for this indication.” The New Drug Application for ADS-5102 has a PDUFA date of August 24, 2017.
- Presented expanded analysis from the ADS-5102 (amantadine extended release capsules) open-label study at the 21st International Congress of Parkinson's Disease and Movement Disorders (MDS) meeting showing tolerability and durability out to 88 weeks. The new subgroup analyses also showed that patients previously treated with immediate-release amantadine, who switched directly to ADS-5102, experienced a statistically significant benefit from ADS-5102 comparable to patients not previously treated with ADS-5102.
- Published ADS-5102 Phase 3 EASE LID clinical trial data in JAMA Neurology online. The data demonstrated that ADS-5102 significantly reduced both dyskinesia and OFF time at six months in Parkinson's disease patients with levodopa-induced dyskinesia.
- Presented positive Phase 1a clinical trial data in a podium presentation at the 14th Antiepileptic Drug and Device Trials Conference for ADS-4101 (lacosamide modified release capsules). The Phase 1 results showed that treatment with ADS-4101 resulted in reduced adverse events (including dizziness) compared to an equivalent dose of VIMPAT® (lacosamide) immediate-release tablets in healthy volunteers.
- Initiated ADS-4101 Phase 1b steady-state study to evaluate the tolerability and pharmacodynamic profile of three ascending doses of ADS-4101 administered once daily at bedtime compared to ascending doses of twice daily VIMPAT (lacosamide) tablets. Announcement of topline data from the trial is expected in the third quarter of 2017.
- Signed $100 million royalty-backed note agreement with HealthCare Royalty Partners.
- Appointed Alfred G. Merriweather as Chief Financial Officer.
Second Quarter 2017 Financial Results
Adamas reported a net loss of $20.7 million, or $0.93 per share, basic and diluted, for the second quarter of 2017, compared to a net loss of $16.9 million, or $0.78 per share, basic and diluted, for the second quarter of 2016. The net losses for the second quarters of 2017 and 2016 included $3.8 million and $2.6 million, respectively, in non-cash stock-based compensation expense.
Research and development expenses were $7.2 million for the second quarter of 2017, including $0.9 million in stock-based compensation expense, compared to $9.2 million for the comparable quarter of 2016, including $0.7 million in stock-based compensation expense. The 22 percent decrease was mainly attributable to the completion of two Phase 3 clinical trials of ADS-5102 for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease, in addition to decreased level of pre-commercial manufacturing activities. The decrease was offset in part by increased activity and expense related to clinical work associated with ADS-4101 for the treatment of partial onset seizures in patients with epilepsy.
General and administrative expenses for the second quarter ended June 30, 2017, were $13.1 million, including $2.9 million in stock-based compensation expense, compared to $8.1 million for the quarter ended June 30, 2016, which included $1.9 million in stock-based compensation expense. The 62 percent increase in general and administrative expenses was primarily due to growth in commercial headcount-related expenses and marketing expenses in preparation for the potential commercial launch of ADS-5102 for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease, pending regulatory approval.
Six-month 2017 Financial Results
Adamas reported a net loss for the six months ended June 30, 2017, of $36.8 million, or $1.65 per share, basic and diluted, compared with a net loss for the same period in 2016 of $30.7 million, or $1.43 per share, basic and diluted. Research and development expenses for the six months ended June 30, 2017, were $14.3 million, including $1.7 million in stock-based compensation expense, compared to $16.7 million for the six months ended June 30, 2016, which included $1.4 million in stock-based compensation expense. General and administrative expenses for the six months ended June 30, 2017, were $22.3 million, including $4.9 million in stock-based compensation expense, compared to $14.7 million for the six months ended June 30, 2016, which included $3.8 million in stock-based compensation expense.
Adamas ended the quarter with $144.9 million of cash, cash equivalents, and available-for-sale securities, compared to $135.9 million at December 31, 2016. This includes $35 million in funding from HealthCare Royalty Partners received at the initial closing of the $100 million royalty-backed loan financing.
Investor Conference Call and Webcast
Adamas will host a conference call and webcast today, August 8, 2017, at 4:30 p.m. Eastern Time. The conference call may be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at http://ir.adamaspharma.com/events.cfm and will be available for replay until September 8, 2017.
About Adamas Pharmaceuticals, Inc.
At Adamas, we believe in the power and the promise of medicines derived from a deep understanding of time-dependent biology. Our expertise lies in uncovering and mapping the relationship between disease and drug activity timing patterns. From there, we strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. This unique understanding of time-dependent biological processes informs our every innovation, targeting advancement in treatment of chronic neurologic disorders. Our proprietary portfolio includes ADS-5102, a high-dose amantadine therapy taken once-daily at bedtime, in development for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease as well as walking impairment in people with multiple sclerosis, and ADS-4101, a high-dose lacosamide therapy taken once-daily at bedtime, in development for the treatment of partial onset seizures in patients with epilepsy. The NDA for ADS-5102 is currently under review by the U.S. Food and Drug Administration with a PDUFA date of August 24, 2017. Additionally, Adamas’ licensed assets are currently marketed by Allergan under the brand names NAMENDA XR® and NAMZARIC®, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz Pharma GmbH & Co. KGaA. VIMPAT® is a trademark of UCB.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding the potential approval of ADS-5102 for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease. Words such as “potentially” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. For a description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to Adamas’ research, clinical, development, and commercial activities relating to ADS-5102 and ADS-4101, the regulatory and competitive environment and Adamas’ business in general, see Adamas’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2017. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release.
— Financial Tables Attached —
|Adamas Pharmaceuticals, Inc.|
|Unaudited Condensed Consolidated Statements of Operations|
|(in thousands, except per share data)|
|Three Months Ended|
|Six Months Ended|
|Research and development||7,176||9,224||14,264||16,746|
|General and administrative, net||13,115||8,058||22,259||14,699|
|Total operating expenses||20,291||17,282||36,523||31,445|
|Loss from operations||(20,289||)||(17,060||)||(36,521||)||(31,048||)|
|Interest and other income, net||222||184||426||344|
|Loss before income taxes||(20,796||)||(16,876||)||(36,824||)||(30,704||)|
|Benefit for income taxes||(51||)||—||(51||)||—|
|Net loss per share, basic and diluted||$||(0.93||)||$||(0.78||)||$||(1.65||)||$||(1.43||)|
|Weighted average shares used in computing net loss per share, basic and diluted||22,392||21,650||22,300||21,452|
|Adamas Pharmaceuticals, Inc.|
|Unaudited Consolidated Balance Sheet Data|
|Cash, cash equivalents, and available-for-sale securities||$||144,929||$||135,944|
|Total current liabilities||11,049||9,743|
|Total stockholders' equity||103,904||132,183|
Contact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. Phone: 510-450-3567 Email: firstname.lastname@example.org
Source:Adamas Pharmaceuticals, Inc.